title: On-demand treatment with anakinra: a treatment option for selected TRAPS patients.
authors.affiliation: French Reference Center for Autoinflammatory Diseases, Department of Pediatrics, Centre Hospitalier de Versailles, Le Chesnay.
authors.forename: Claire
authors.initials: C
authors.lastname: Grimwood
authors.affiliation: Service de médecine de l'enfant et de l'adolescent, CHU de Rennes - Hôpital Sud, Rennes and.
authors.forename: Véronique
authors.initials: V
authors.lastname: Despert
authors.affiliation: Laboratoire de génétique moléculaire, Hôpital Saint Antoine, Université Pierre et Marie Curie, Paris, FranceRevised version accepted 6 March 2015.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Jeru
authors.affiliation: French Reference Center for Autoinflammatory Diseases, Department of Pediatrics, Centre Hospitalier de Versailles, Le Chesnay, vhentgen@ch-versailles.fr.
authors.forename: Véronique
authors.initials: V
authors.lastname: Hentgen
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002648:Child; D005334:Fever / Q000188:drug therapy* / Q000235:genetics; D056660:Hereditary Autoinflammatory Diseases / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D009154:Mutation / Q000235:genetics; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D047888:Receptors, Tumor Necrosis Factor, Type I; C506235:TNFRSF1A protein, human